SNY
Sanofi
Price Chart
Latest Quote
$42.38
-0.12 (-0.28%)
Current Price
| Previous Close | $42.50 |
| Open | $42.34 |
| Day High | $42.46 |
| Day Low | $41.86 |
| Volume | 3,861,473 |
Stock Information
Note: Financial values converted from EUR to USD
| Quarterly Dividend / Yield | $2.42 / 5.49% |
| Shares Outstanding | 2.39B |
| Quarterly Dividend Yield | 5.49% |
| Quarterly Dividend | $2.42 |
| Total Debt | $22.96B |
| Cash Equivalents | $6.36B |
| Revenue | $54.31B |
| Net Income | $5.54B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $101.45B |
| P/E Ratio | 18.43 |
| EPS (TTM) | $2.30 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $120.90B |
| Sales | $54.31B |
| Income | $5.54B |
| Book/sh | $34.89 |
| Cash/sh | $2.32 |
| Employees | 75K |
Financial Ratios
| Quick Ratio | 0.20 |
| Current Ratio | 1.00 |
| Debt/Eq | 27.37 |
| EPS Growth TTM | -13.80% |
Returns & Margins
| ROA | 4.67% |
| ROE | 6.58% |
| Gross Margin | 72.36% |
| Operating Margin | 20.00% |
| Profit Margin | 15.95% |
Ownership
| Insider Ownership | 0.00% |
| Institutional Ownership | 8.90% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 8.02 |
| PEG | 3.67 |
| P/S | 2.14 |
| P/B | 1.21 |
Analyst Data
| Recommendation | none |
| Target Price | $55.90 |
Technical Indicators
| SMA20 | $43.83 |
| SMA50 | $43.91 |
| SMA200 | $45.04 |
| RSI | 43.65 |
| ATR | 0.9479 |
| Shares Float | 2.17B |
| Short Float | 0.32% |
| Short Ratio | 2.58 |
| Volatility | 0.28 |
| Rel Volume | 1.46 |
Performance History
| Week | -3.92% |
| Month | -2.69% |
| Quarter | -1.34% |
| 6 Months | -5.71% |
| YTD | -7.25% |
| Year | -7.24% |
| 3 Years | -3.62% |
| 5 Years | -2.40% |
| 10 Years | +63.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $42.38 | 4,085,500 |
| 2026-06-17 | $42.50 | 8,394,400 |
| 2026-06-16 | $44.05 | 1,574,400 |
| 2026-06-15 | $43.80 | 1,848,500 |
| 2026-06-12 | $44.25 | 1,632,900 |
| 2026-06-11 | $44.11 | 3,207,000 |
| 2026-06-10 | $43.57 | 4,027,200 |
| 2026-06-09 | $44.73 | 2,832,100 |
| 2026-06-08 | $43.88 | 1,879,100 |
| 2026-06-05 | $45.02 | 2,603,600 |
| 2026-06-04 | $44.38 | 2,230,300 |
| 2026-06-03 | $42.37 | 2,472,700 |
| 2026-06-02 | $42.80 | 1,963,700 |
| 2026-06-01 | $42.96 | 2,720,200 |
| 2026-05-29 | $43.67 | 2,426,300 |
| 2026-05-28 | $44.29 | 2,137,500 |
| 2026-05-27 | $44.43 | 2,297,400 |
| 2026-05-26 | $44.15 | 2,538,400 |
| 2026-05-22 | $44.29 | 2,763,300 |
| 2026-05-21 | $44.92 | 2,236,800 |
| 2026-05-20 | $44.67 | 2,736,900 |
| 2026-05-19 | $43.55 | 2,251,000 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
đ° Latest News
Is Sanofi (SNY) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-19T14:56:51Z
How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story
Trefis âĸ 2026-06-19T00:56:28Z
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
MT Newswires âĸ 2026-06-17T15:10:44ZSanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
Zacks âĸ 2026-06-15T16:12:00Z
European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading
MT Newswires âĸ 2026-06-15T15:09:48ZSanofiâs Tzield Approval Adds New Dimension To Endocrinology Story
Simply Wall St. âĸ 2026-06-15T04:17:28Z
Sanofi (ENXTPA:SAN) Stock After Mixed CIDP Trial Halt And Sarclisa EU Approval How Does Valuation Look Now
Simply Wall St. âĸ 2026-06-14T20:06:12Z
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results
Stocktwits âĸ 2026-06-12T21:13:58Z
Drug developers eye sportâs biggest stage as World Cup fever builds
Pharmaceutical Technology âĸ 2026-06-11T16:21:38Z
Novavax Pivots To Matrix M Licensing As Sanofi Takes Europe
Simply Wall St. âĸ 2026-06-11T00:20:08Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $10,624,927,440 | $13,204,785,737 | $11,743,524,261 | $12,287,141,408 |
| Cost Of Revenue | $15,157,393,480 | $15,338,599,196 | $14,668,370,363 | $13,801,835,338 |
| Total Revenue | $54,264,142,372 | $51,441,514,879 | $48,342,432,512 | $47,114,647,631 |
| Operating Revenue | $50,674,875,313 | $47,718,666,683 | $43,927,285,557 | $43,734,464,090 |
| Expenses | ||||
| Interest Expense | $727,146,013 | $817,748,870 | $746,892,789 | $540,132,422 |
| Total Expenses | $43,116,506,137 | $41,076,780,261 | $38,247,183,318 | $34,423,278,088 |
| Other Income Expense | $-3,825,066,804 | $-2,015,332,799 | $-2,107,097,231 | $-889,766,527 |
| Net Non Operating Interest Income Expense | $-149,843,188 | $-569,171,799 | $-727,146,013 | $-259,031,247 |
| Total Other Finance Cost | $-192,821,467 | $260,192,822 | $607,503,777 | $-3,484,725 |
| Interest Expense Non Operating | $727,146,013 | $817,748,870 | $746,892,789 | $540,132,422 |
| Operating Expense | $27,959,112,657 | $25,738,181,066 | $23,578,812,955 | $20,621,442,750 |
| Other Operating Expenses | $4,890,231,171 | $3,711,232,445 | $2,793,588,116 | $823,556,746 |
| Selling And Marketing Expense | $811,940,995 | $739,923,339 | $630,735,279 | - |
| General And Administrative Expense | $11,084,911,179 | $10,666,744,143 | $10,376,350,368 | - |
| Other Non Operating Income Expenses | - | - | - | $-429,782,787 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $5,737,019,419 | $6,384,016,750 | $5,879,893,156 | $9,257,753,547 |
| Net Interest Income | $-149,843,188 | $-569,171,799 | $-727,146,013 | $-259,031,247 |
| Interest Income | $384,481,358 | $508,769,894 | $627,250,554 | $277,616,449 |
| Normalized Income | $8,916,006,114 | $8,037,083,097 | $7,643,533,539 | $9,976,684,900 |
| Net Income From Continuing And Discontinued Operation | $9,075,386,256 | $6,458,357,556 | $6,272,505,540 | $9,723,545,162 |
| Total Operating Income As Reported | $7,369,032,434 | $8,423,742,625 | $8,084,562,696 | $11,803,926,166 |
| Net Income Common Stockholders | $9,075,386,256 | $6,458,357,556 | $6,272,505,540 | $9,723,545,162 |
| Net Income | $9,075,386,256 | $6,458,357,556 | $6,272,505,540 | $9,723,545,162 |
| Net Income Including Noncontrolling Interests | $9,119,526,110 | $6,525,728,912 | $6,314,322,244 | $9,854,803,148 |
| Net Income Discontinuous Operations | $3,338,366,837 | $74,340,806 | $392,612,384 | $465,791,615 |
| Net Income Continuous Operations | $5,781,159,273 | $6,451,388,105 | $5,921,709,860 | $9,389,011,533 |
| Earnings From Equity Interest Net Of Tax | $-180,044,140 | $69,694,506 | $-157,974,214 | $63,886,631 |
| Pretax Income | $7,172,726,243 | $7,780,230,020 | $7,261,005,950 | $11,542,571,769 |
| Special Income Charges | $-3,778,603,800 | $-1,940,991,992 | $-2,010,686,498 | $-887,443,376 |
| Interest Income Non Operating | $384,481,358 | $508,769,894 | $627,250,554 | $277,616,449 |
| Operating Income | $11,147,636,235 | $10,364,734,617 | $10,095,249,194 | $12,691,369,543 |
| Depreciation Amortization Depletion Income Statement | $2,062,957,378 | $2,031,594,850 | $2,219,770,016 | $2,095,481,480 |
| Depreciation And Amortization In Income Statement | $2,062,957,378 | $2,031,594,850 | $2,219,770,016 | $2,095,481,480 |
| Amortization Of Intangibles Income Statement | $2,062,957,378 | $2,031,594,850 | $2,219,770,016 | $2,095,481,480 |
| Gross Profit | $39,106,748,892 | $36,102,915,683 | $33,674,062,149 | $33,312,812,293 |
| Per Share | ||||
| Diluted EPS | $3.72 | $2.67 | $2.50 | $3.12 |
| Basic EPS | $3.72 | $2.67 | $2.50 | $3.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $-646,080,110 | $-362,266,451 | $-343,456,849 | $-170,835,173 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $18,320,362,477 | $14,778,719,997 | $15,259,612,089 | $16,582,646,128 |
| Total Unusual Items | $-3,825,066,804 | $-2,015,332,799 | $-2,107,097,231 | $-889,766,527 |
| Total Unusual Items Excluding Goodwill | $-3,825,066,804 | $-2,015,332,799 | $-2,107,097,231 | $-889,766,527 |
| Reconciled Depreciation | $6,595,423,418 | $4,165,408,309 | $5,144,616,118 | $3,610,175,411 |
| EBITDA (Bullshit earnings) | $14,495,295,673 | $12,763,387,199 | $13,152,514,857 | $15,692,879,601 |
| EBIT | $7,899,872,255 | $8,597,978,890 | $8,007,898,739 | $12,082,704,190 |
| Diluted Average Shares | $2,835,172,504 | $2,907,190,160 | $2,907,887,105 | $2,908,351,735 |
| Basic Average Shares | $2,835,172,504 | $2,907,190,160 | $2,907,887,105 | $2,908,351,735 |
| Diluted NI Availto Com Stockholders | $9,075,386,256 | $6,458,357,556 | $6,272,505,540 | $9,723,545,162 |
| Minority Interests | $-44,139,854 | $-67,371,356 | $-41,816,704 | $-131,257,986 |
| Tax Provision | $1,211,522,829 | $1,398,536,420 | $1,181,321,877 | $2,217,446,866 |
| Gain On Sale Of Ppe | $563,363,924 | $626,088,979 | $562,202,348 | - |
| Gain On Sale Of Business | $563,363,924 | $626,088,979 | $562,202,348 | - |
| Other Special Charges | $296,201,650 | $545,940,297 | $227,668,720 | $166,105,239 |
| Impairment Of Capital Assets | $2,603,089,799 | $288,070,625 | $1,040,771,290 | $-498,315,718 |
| Restructuring And Mergern Acquisition | $1,442,676,274 | $1,733,070,049 | $1,304,448,837 | $1,219,653,855 |
| Gain On Sale Of Security | $-46,463,004 | $-74,340,806 | $-96,410,733 | $-2,323,150 |
| Amortization | $2,062,957,378 | $2,031,594,850 | $2,219,770,016 | $2,095,481,480 |
| Research And Development | $9,109,071,934 | $8,588,686,289 | $7,558,369,176 | $7,551,399,725 |
| Selling General And Administration | $11,896,852,174 | $11,406,667,482 | $11,007,085,648 | $10,151,004,799 |
| Other Gand A | $11,084,911,179 | $10,666,744,143 | $10,376,350,368 | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,431,409,006 | $13,351,144,199 | $368,219,307 | $3,777,442,225 |
| Total Assets | $147,293,530,556 | $154,254,850,130 | $146,897,433,446 | $147,197,119,822 |
| Total Non Current Assets | $111,340,458,060 | $104,785,689,771 | $111,271,925,129 | $107,574,631,586 |
| Non Current Prepaid Assets | $203,275,642 | $176,559,415 | $132,419,561 | $332,210,479 |
| Non Current Deferred Assets | $9,998,838,461 | $9,254,268,822 | $7,465,443,168 | $6,250,435,613 |
| Non Current Deferred Taxes Assets | $9,998,838,461 | $9,254,268,822 | $7,465,443,168 | $6,250,435,613 |
| Non Current Note Receivables | $454,175,864 | $583,110,700 | $686,490,884 | $525,031,945 |
| Non Current Accounts Receivable | $921,129,054 | $650,482,056 | $218,376,119 | $281,101,174 |
| Financial Assets | $10,454,176 | $0 | $0 | $0 |
| Investmentin Financial Assets | $4,173,539,334 | $3,418,515,519 | $2,604,251,374 | $2,425,368,809 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $1,166,221,400 | $1,192,937,628 | $938,552,681 | $955,976,307 |
| Goodwill And Other Intangible Assets | $78,477,175,331 | $76,679,057,076 | $85,634,801,097 | $83,089,790,053 |
| Other Intangible Assets | $30,504,123,701 | $26,285,282,938 | $28,248,344,857 | $25,136,485,164 |
| Current Assets | $35,953,072,495 | $49,469,160,359 | $35,625,508,317 | $39,621,326,661 |
| Hedging Assets Current | $114,995,935 | $252,061,797 | $233,476,595 | $239,284,471 |
| Assets Held For Sale Current | $241,607,621 | $15,668,486,524 | $17,423,626 | $98,733,884 |
| Prepaid Assets | $1,066,325,942 | $1,039,609,715 | $892,089,677 | $829,364,621 |
| Inventory | $11,864,328,071 | $10,954,814,768 | $11,227,784,917 | $10,407,712,896 |
| Receivables | $12,830,758,555 | $12,346,381,738 | $12,823,789,104 | $12,482,286,025 |
| Other Receivables | $1,719,131,148 | $1,679,637,595 | $1,681,960,745 | $1,498,431,879 |
| Taxes Receivable | $1,342,780,816 | $1,749,332,101 | $1,346,265,541 | $1,198,745,503 |
| Accounts Receivable | $9,768,846,591 | $8,917,412,043 | $9,795,562,818 | $9,785,108,642 |
| Allowance For Doubtful Accounts Receivable | $-116,157,510 | $-116,157,510 | $-110,349,635 | $-131,257,986 |
| Gross Accounts Receivable | $9,885,004,101 | $9,033,569,553 | $9,905,912,453 | $9,916,366,629 |
| Cash Cash Equivalents And Short Term Investments | $9,835,056,372 | $9,207,805,818 | $10,430,944,398 | $15,563,944,765 |
| Cash And Cash Equivalents | $8,894,180,541 | $8,643,280,319 | $10,117,319,121 | $14,793,820,474 |
| Cash Equivalents | $7,875,479,178 | $7,168,079,942 | $8,420,257,900 | $13,185,038,960 |
| Cash Financial | $1,018,701,363 | $1,475,200,377 | $1,697,061,221 | $1,608,781,514 |
| Debt | ||||
| Net Debt | $12,699,500,568 | $9,941,921,281 | $8,923,219,918 | $7,312,115,255 |
| Total Debt | $23,613,660,208 | $20,799,163,741 | $21,398,536,492 | $24,639,331,021 |
| Long Term Debt And Capital Lease Obligation | $18,254,152,696 | $15,606,923,044 | $18,703,682,260 | $19,469,160,251 |
| Long Term Debt | $16,550,122,025 | $13,696,132,004 | $16,665,117,960 | $17,257,521,261 |
| Current Debt And Capital Lease Obligation | $5,359,507,511 | $5,192,240,697 | $2,694,854,232 | $5,170,170,770 |
| Current Debt | $5,043,559,084 | $4,889,069,596 | $2,375,421,080 | $4,848,414,467 |
| Other Current Borrowings | $5,043,559,084 | $4,889,069,596 | $2,375,421,080 | $4,848,414,467 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $63,996,980,135 | $63,818,097,569 | $60,530,840,036 | $59,902,427,907 |
| Total Non Current Liabilities Net Minority Interest | $31,072,133,925 | $29,944,244,503 | $32,412,591,590 | $32,054,826,460 |
| Other Non Current Liabilities | $1,267,278,434 | $3,231,501,928 | $3,109,536,543 | $1,385,759,094 |
| Derivative Product Liabilities | $111,511,210 | $140,550,587 | $190,498,316 | - |
| Tradeand Other Payables Non Current | $4,229,294,939 | $1,756,301,551 | $2,139,621,334 | $2,298,757,123 |
| Non Current Deferred Liabilities | $1,935,184,117 | $2,515,971,667 | $2,157,044,961 | $2,138,459,759 |
| Non Current Deferred Taxes Liabilities | $1,935,184,117 | $2,515,971,667 | $2,157,044,961 | $2,138,459,759 |
| Current Liabilities | $32,924,846,210 | $33,873,853,066 | $28,118,248,446 | $27,847,601,447 |
| Other Current Liabilities | $14,019,049,882 | $14,574,282,780 | $11,543,733,344 | $9,412,243,035 |
| Current Deferred Liabilities | $0 | $0 | $0 | $312,463,702 |
| Payables And Accrued Expenses | $10,506,446,780 | $11,108,142,681 | $10,761,993,302 | $9,897,781,427 |
| Payables | $10,506,446,780 | $11,108,142,681 | $10,761,993,302 | $9,897,781,427 |
| Other Payable | $650,482,056 | $1,019,862,938 | $1,097,688,470 | $829,364,621 |
| Total Tax Payable | $1,305,610,412 | $1,317,226,163 | $1,152,282,499 | $1,154,605,649 |
| Income Tax Payable | $872,342,900 | $809,617,845 | $693,460,335 | $666,744,107 |
| Accounts Payable | $8,550,354,311 | $8,771,053,580 | $8,512,022,333 | $7,913,811,156 |
| Equity | ||||
| Common Stock Equity | $82,908,584,338 | $90,030,201,276 | $86,003,020,404 | $86,867,232,278 |
| Total Equity Gross Minority Interest | $83,296,550,421 | $90,436,752,561 | $86,366,593,410 | $87,294,691,915 |
| Stockholders Equity | $82,908,584,338 | $90,030,201,276 | $86,003,020,404 | $86,867,232,278 |
| Other Equity Interest | $6,472,296,457 | $6,109,885,026 | $5,742,827,294 | $5,410,616,816 |
| Gains Losses Not Affecting Retained Earnings | $74,847,253,144 | $81,961,900,631 | $78,333,140,019 | $79,201,998,194 |
| Other Equity Adjustments | $74,847,253,144 | $81,961,900,631 | $78,333,140,019 | $79,201,998,194 |
| Long Term Equity Investment | $3,401,091,893 | $307,817,402 | $404,228,135 | $786,386,343 |
| Other | ||||
| Treasury Shares Number | $13,777,024 | $11,071,066 | $15,623,636 | $9,524,916 |
| Ordinary Shares Number | $1,402,766,310 | $1,456,140,835 | $1,453,536,515 | $1,464,555,391 |
| Share Issued | $1,416,543,334 | $1,467,211,901 | $1,469,160,150 | $1,474,080,307 |
| Tangible Book Value | $4,431,409,006 | $13,351,144,199 | $368,219,307 | $3,777,442,225 |
| Invested Capital | $104,502,265,447 | $108,615,402,876 | $105,043,559,443 | $108,973,168,007 |
| Working Capital | $3,028,226,286 | $15,595,307,293 | $7,507,259,871 | $11,773,725,214 |
| Capital Lease Obligations | $2,019,979,099 | $2,213,962,141 | $2,357,997,453 | $2,533,395,293 |
| Total Capitalization | $99,458,706,362 | $103,726,333,280 | $102,668,138,364 | $104,124,753,539 |
| Minority Interest | $387,966,083 | $406,551,285 | $363,573,006 | $427,459,637 |
| Treasury Stock | $1,245,208,507 | $975,723,084 | $1,375,304,918 | $820,072,021 |
| Additional Paid In Capital | $1,161,575 | $0 | $363,573,006 | $145,196,888 |
| Capital Stock | $2,833,081,669 | $2,934,138,703 | $2,938,785,003 | $2,929,492,402 |
| Common Stock | $2,833,081,669 | $2,934,138,703 | $2,938,785,003 | $2,929,492,402 |
| Long Term Capital Lease Obligation | $1,704,030,672 | $1,910,791,040 | $2,038,564,301 | $2,211,638,990 |
| Long Term Provisions | $5,274,712,529 | $6,692,995,726 | $6,112,208,176 | $6,762,690,232 |
| Current Deferred Revenue | $0 | $0 | $0 | $312,463,702 |
| Current Capital Lease Obligation | $315,948,427 | $303,171,101 | $319,433,152 | $321,756,303 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,261,586,720 | $2,240,678,368 | $2,446,277,161 | $2,506,679,066 |
| Current Provisions | $778,255,317 | $758,508,540 | $671,390,408 | $548,263,447 |
| Defined Pension Benefit | $225,345,569 | $181,205,716 | $314,786,852 | $312,463,702 |
| Investments And Advances | $7,679,172,986 | $3,785,573,251 | $3,096,759,217 | $3,211,755,152 |
| Other Investments | $104,541,759 | $59,240,330 | $88,279,708 | - |
| Available For Sale Securities | $3,007,317,934 | $2,225,577,892 | $1,665,698,693 | $1,469,392,502 |
| Investmentsin Joint Venturesat Cost | $198,629,342 | $212,568,243 | $216,052,969 | - |
| Investmentsin Associatesat Cost | $3,202,462,551 | $95,249,158 | $188,175,166 | - |
| Goodwill | $47,973,051,630 | $50,393,774,138 | $57,386,456,240 | $57,953,304,889 |
| Net PPE | $13,370,890,976 | $13,475,432,735 | $13,722,848,231 | $13,571,843,468 |
| Accumulated Depreciation | $-16,802,183,822 | $-17,508,421,482 | $-18,153,095,663 | $-17,553,722,911 |
| Gross PPE | $30,173,074,798 | $30,983,854,217 | $31,875,943,894 | $31,125,566,380 |
| Construction In Progress | $4,164,246,734 | $4,150,307,832 | $4,006,272,520 | $3,480,079,000 |
| Other Properties | $2,903,937,750 | $3,035,195,736 | $3,103,728,667 | $3,336,043,687 |
| Machinery Furniture Equipment | $14,728,772,268 | $14,918,109,009 | $15,579,045,241 | $15,522,128,061 |
| Buildings And Improvements | $8,203,043,356 | $8,646,765,044 | $8,922,058,343 | $8,512,022,333 |
| Land And Improvements | $173,074,690 | $233,476,595 | $264,839,123 | $275,293,299 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $3,309,327,460 | $3,115,344,418 | $3,252,410,280 | $2,905,099,325 |
| Work In Process | $6,877,686,167 | $6,151,701,730 | $6,174,933,232 | $5,790,451,874 |
| Raw Materials | $1,677,314,444 | $1,687,768,620 | $1,800,441,405 | $1,712,161,697 |
| Other Short Term Investments | $940,875,831 | $564,525,499 | $313,625,277 | $770,124,291 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $8,377,279,621 | $6,837,031,039 | $8,539,900,135 | $9,783,947,067 |
| Operating Activities | ||||
| Operating Cash Flow | $12,486,932,325 | $10,548,263,483 | $11,915,437,376 | $12,226,739,503 |
| Cash From Discontinued Operating Activities | $219,537,694 | $550,586,597 | $1,146,474,624 | $1,031,478,689 |
| Cash Flow From Continuing Operating Activities | $12,267,394,631 | $9,997,676,886 | $10,768,962,752 | $11,195,260,814 |
| Operating Gains Losses | $291,555,350 | $-6,969,451 | $219,537,694 | $-465,791,615 |
| Investing Activities | ||||
| Capital Expenditure | $-4,109,652,704 | $-3,711,232,445 | $-3,375,537,241 | $-2,442,792,435 |
| Investing Cash Flow | $-2,842,374,270 | $-5,119,061,466 | $-7,201,765,620 | $-2,410,268,332 |
| Cash From Discontinued Investing Activities | $12,082,704,190 | $-126,611,686 | $-1,451,968,875 | $48,786,154 |
| Cash Flow From Continuing Investing Activities | $-14,925,078,460 | $-4,992,449,780 | $-5,749,796,745 | $-2,459,054,487 |
| Net Other Investing Changes | $-92,926,008 | $-46,463,004 | $-260,192,822 | $-16,262,051 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-5,842,722,753 | $-350,795,680 | $-688,814,034 | $-577,302,825 |
| Issuance Of Capital Stock | $205,598,793 | $217,214,544 | $226,507,145 | $218,376,119 |
| Financing Cash Flow | $-9,533,046,846 | $-6,694,157,301 | $-9,353,002,705 | $-6,761,528,657 |
| Cash From Discontinued Financing Activities | $-55,755,605 | $-13,938,901 | $-4,646,300 | $-16,262,051 |
| Cash Flow From Continuing Financing Activities | $-9,477,291,241 | $-6,680,218,400 | $-9,348,356,405 | $-6,745,266,606 |
| Net Other Financing Charges | $-44,139,854 | $-44,139,854 | $-68,532,931 | $-112,672,785 |
| Cash Dividends Paid | $-5,543,036,377 | $-5,464,049,270 | $-5,173,655,495 | $-4,841,445,017 |
| Common Stock Dividend Paid | $-5,543,036,377 | $-5,464,049,270 | $-5,173,655,495 | $-4,841,445,017 |
| Net Common Stock Issuance | $-5,637,123,960 | $-133,581,137 | $-462,306,890 | $-358,926,706 |
| Common Stock Issuance | $205,598,793 | $217,214,544 | $226,507,145 | $218,376,119 |
| Other | ||||
| Repayment Of Debt | $-3,432,454,421 | $-1,106,981,070 | $-4,571,959,594 | $-3,482,402,150 |
| Issuance Of Debt | $6,457,195,981 | $0 | $55,755,605 | $1,799,279,830 |
| Interest Paid Supplemental Data | $563,363,924 | $681,844,584 | $649,320,481 | $441,398,538 |
| Income Tax Paid Supplemental Data | $3,351,144,164 | $3,822,743,654 | $3,046,811,487 | $2,848,182,145 |
| End Cash Position | $8,894,180,541 | $8,643,280,319 | $10,117,319,121 | $14,793,820,474 |
| Beginning Cash Position | $8,643,280,319 | $10,117,319,121 | $14,793,820,474 | $11,729,585,360 |
| Effect Of Exchange Rate Changes | $-54,594,030 | $-15,100,476 | $-37,170,403 | $9,292,601 |
| Changes In Cash | $305,494,251 | $-1,458,938,326 | $-4,639,330,949 | $3,054,942,513 |
| Other Cash Adjustment Inside Changein Cash | $193,983,042 | $-193,983,042 | $0 | $0 |
| Common Stock Payments | $-5,842,722,753 | $-350,795,680 | $-688,814,034 | $-577,302,825 |
| Net Issuance Payments Of Debt | $1,747,008,950 | $-1,038,448,139 | $-3,643,861,089 | $-1,432,222,098 |
| Net Short Term Debt Issuance | $-1,277,732,610 | $68,532,931 | $872,342,900 | $250,900,222 |
| Net Long Term Debt Issuance | $3,024,741,560 | $-1,106,981,070 | $-4,516,203,989 | $-1,683,122,320 |
| Long Term Debt Payments | $-3,432,454,421 | $-1,106,981,070 | $-4,571,959,594 | $-3,482,402,150 |
| Long Term Debt Issuance | $6,457,195,981 | $0 | $55,755,605 | $1,799,279,830 |
| Net Business Purchase And Sale | $-11,706,353,858 | $-2,931,815,552 | $-3,051,457,788 | $-1,556,510,634 |
| Sale Of Business | $0 | $0 | $48,786,154 | $155,651,063 |
| Purchase Of Business | $-11,706,353,858 | $-2,931,815,552 | $-3,100,243,942 | $-1,712,161,697 |
| Net PPE Purchase And Sale | $-3,125,798,594 | $-2,014,171,223 | $-2,438,146,135 | $-886,281,801 |
| Sale Of PPE | $983,854,110 | $1,697,061,221 | $937,391,106 | $1,556,510,634 |
| Purchase Of PPE | $-4,109,652,704 | $-3,711,232,445 | $-3,375,537,241 | $-2,442,792,435 |
| Change In Working Capital | $2,085,027,305 | $-714,368,686 | $479,730,516 | $-922,290,629 |
| Change In Other Working Capital | $3,064,235,114 | $-1,044,256,015 | $1,734,231,624 | $329,887,328 |
| Change In Payables And Accrued Expense | $462,306,890 | $916,482,754 | $299,686,376 | $394,935,534 |
| Change In Payable | $462,306,890 | $916,482,754 | $299,686,376 | $394,935,534 |
| Change In Account Payable | $462,306,890 | $916,482,754 | $299,686,376 | $394,935,534 |
| Change In Inventory | $-45,301,429 | $-554,071,323 | $-1,005,924,037 | $-1,066,325,942 |
| Change In Receivables | $-1,396,213,270 | $-32,524,103 | $-548,263,447 | $-580,787,550 |
| Changes In Account Receivables | $-1,396,213,270 | $-32,524,103 | $-548,263,447 | $-580,787,550 |
| Other Non Cash Items | $507,608,319 | $157,974,214 | $355,441,981 | $274,131,724 |
| Provisionand Write Offof Assets | $-116,157,510 | $943,198,981 | $121,965,386 | $55,755,605 |
| Deferred Tax | $-2,833,081,669 | $-931,583,230 | $-1,432,222,098 | $-614,473,228 |
| Deferred Income Tax | $-2,833,081,669 | $-931,583,230 | $-1,432,222,098 | $-614,473,228 |
| Depreciation Amortization Depletion | $6,595,423,418 | $4,165,408,309 | $5,144,616,118 | $3,610,175,411 |
| Depreciation And Amortization | $6,595,423,418 | $4,165,408,309 | $5,144,616,118 | $3,610,175,411 |
| Depreciation | $6,595,423,418 | $4,165,408,309 | $5,144,616,118 | $3,610,175,411 |
| Pension And Employee Benefit Expense | $363,573,006 | $322,917,878 | $302,009,526 | $271,808,573 |
| Earnings Losses From Equity Investments | $336,856,779 | $95,249,158 | $340,341,504 | $-52,270,880 |
| Net Income From Continuing Operations | $5,737,019,419 | $6,384,016,750 | $5,879,893,156 | $9,257,753,547 |
| Net Investment Purchase And Sale | - | - | $-155,651,063 | $-566,848,649 |
| Purchase Of Investment | - | - | $-155,651,063 | $-566,848,649 |
Fetched: 2026-06-17